JPRN-UMIN000015709招募中未知
Efficacy and Safety of Yokukansan in Schizophrenia: A Randomized, Multi-center, Double-Blind, Placebo-Controlled Trial - Yokukansan for Schizophrenia
Shimane University School of Medicine0 个研究点目标入组 60 人开始时间: 2014年11月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Exclusion criteria included pregnancy, lactation, other clinical significant or unstable conditions, and history of alcohol or substance abuse in the last 6 months. No patients had been treated by clozapine in this clinical trial. Because the clozapine has not been available in Japan until 2009, therefore it might have been difficult to include patients who had gone clozapine trial in the past.
研究者
相似试验
招募中
2 期
Efficacy and safety of Yokukansan for the treatment-resistant schizophrenia: randomized, double-blind, placebo-controlled multicenter trialTreatment-Rsistant SchizophreniaJPRN-UMIN000005018Department of Psychiatry, Shimane University School of Medicine120
未知
不适用
The safety and efficacy of Yokukansan in treating neuropsychiatric symptoms of patients with Fronto-Temporal Lobar Degeneration (FTLD)Fronto-Temporal Lobar Degeneration (FTLD)JPRN-UMIN000001897Ehime University Graduate School of Medicine20
未知
不适用
Evaluation of efficacy of yokukansan in patients with dementia with Lewy bodies using NPI-D as an indicator.Dementia with Lewy bodiesJPRN-UMIN000001832Department of Geriatric Medicine, Kyorin University School of Medicine20
尚未招募
不适用
Efficacy and Safety of Yokukansan in Autism Spectrum disorder: A Randomized, Multi-center, Double-Blind, Placebo-Controlled TrialAutism Spectrum DisorderJPRN-UMIN000015708Shimane University School of Medicine100
终止
3 期
Augmentation of antipsychotic medication with anticonvulsant in the management of treatment resistant schizophreniaMental and Behavioural DisordersSchizophreniaISRCTN77257074King's College London371